Active Biotech AB engages in the development of pharmaceutical products. The firm specializes in the medical areas where the immune defense is of significant importance, including neurodegenerative diseases, autoimmune, inflammatory disease, and various forms of cancer. Its portfolio comprises orally active immunomodulatory molecules as well as antibody-based immunotherapy. The company was founded on June 15, 1982 and is headquartered in Lund, Sweden.

Exact Sciences is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA (sDNA) technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.

Cancer Research Ventures Ltd. engages in the business of research and experimental development on biotechnology. It provides medical products. The company is headquartered in London, the United Kingdom.

Shionogi & Co., Ltd. engages in the research, development, supply, manufacture and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.

Jena University Hospital is a private company headquartered in Jena, Germany, that operates as a hospital and medical university.

Academisch Ziekenhuis Maastricht operates as medical research centre. The company is headquartered in Maastricht, the Netherlands.

Koken Co., Ltd. is a company headquartered in Tokyo, Japan, that develops and manufactures silicone materials. It was founded in 1959 by Taichiro Akiyama.

Del Mar Pharmaceuticals (BC) Ltd., part of Kintara Therapeutics, Inc., is a company headquartered in Vancouver, BC, Canada, that provides drug development services. It was founded by William James Garner, Dennis M. Brown and Jeffrey A. Bacha. Jeffrey A. Bacha is the current CEO, occupying that position since 2010. Kintara Therapeutics, Inc. acquired Del Mar Pharmaceuticals (BC) Ltd. on January 25, 2013 for $0.65 million.

Seikagaku Corp. manufactures pharmaceuticals and medical devices with glycoconjugates; specifically, glycosaminoglycans (GAG) such as hyaluronic acid; as well as enzymes that act on GAG. It operates through the following segments: Pharmaceuticals and Limulus Amebocyte Lysate (LAL). The Pharmaceuticals segment develops and supplies intra-articular injections for improving joint functions, cross-linked hyaluronate hydrogel for knee osteoarthritis, opthalmic surgical aids, and surgical aids for endoscopic mucosal resection. The LAL segment manufactures and sells endotoxin-detecting reagents in Japan and overseas. The company was founded on June 2, 1947 and is headquartered in Tokyo, Japan.

Gene Logic is a leading integrated genomics company providing comprehensive Genomic Reference Databases and GLP compliant Microarray Services. Over 2/3rd of the top 25 Pharma companies, leading research institutes and emerging biotech companies worldwide have chosen us as their preferred genomics partner and utilize our expertise for understanding underlying mechanisms of diseases, discovery and prioritization of gene targets & biomarkers.

The Research Authority serves as the administrative and financial framework for research activities, scientific experiments and technical analyses carried out by Technion faculty, and TRDF staff. The missions of the Research & Development Division are: - Location, collection, processing and distribution of information concerning local and international research funding - Assistance in locating appropriate funding sources for Technion researchers - R&D information management services and in-campus marketing - Guidance and administrative services for Technion researchers in submitting research proposals to granting agencies and business entities - Management of contractual engagements with granting agencies and business entities - Contractual and budgetary administration of research grants and other accounts

Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clone-SEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers. It was founded in 2009 and headquartered in Seattle, Washington.

Osaka Prefectural Hospital Organization is a Japanese private company located in Osaka. The firm provides medical services.

DNA Chip Research, Inc. engages in the business of contract analysis and Deoxyribonucleic Acid (DNA) chip technology development services. It operates through the following segments: Contract Research and Product Sales. The Contract Research segment offers contract analytical services, genomic medicine analysis, diagnostic support, and research and development services. The Product Sales segment engages in the manufacture and sale of DNA chip, life science and biotechnology information equipment. The company was founded by Kenichi Matsubara on April 1, 1999 and is headquartered in Tokyo, Japan.

Tropix, Inc., a subsidiary of Applied Biosystems, Inc., is an American company located in Bedford, MA, that manufactures DNA tracing and biological products. The firm was acquired by Applera Corp. on April 19, 1996.

SyntheX created a novel cell-based, synthetic biology-driven drug selection platform, that allows for the efficient synthesis and identification of peptides and macrocycles that selectively disrupt intracellular protein-protein interactions of interest. Although the platform has broad application, the initial focus is on oncology. Targets are selected based on the concepts of synthetic lethality and oncogene addiction, with the first program focused on DNA damage repair and working through a novel cell death mechanism that was uncovered.

Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals. Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals.” In accordance with this philosophy, as we implement our business activities we strive to realize our vision, which expresses that “Mitsubishi Tanabe Pharma strive to be a global research-driven pharmaceutical company that is trusted by communities.” As a company that is trusted and highly evaluated by patients and health care professionals as well as by society and shareholders, we will implement management with a focus on transparency and fairness while always keeping in mind the starting point of our business activities: “Everything we do is for the patients.”

Suntory Holdings Ltd. operates as a holding company with interests in the production and distribution of alcoholic and non-alcoholic beverages, health, beauty, and processed food products. Its services include formulation and promotion of group wide management strategies and corporate functions; sale of alcoholic beverages such as whiskey, beer, and wine; soft drinks; and other beverages such as tea and canned coffee. The company was founded by Shinjiro Torii in 1899 and is headquartered in Osaka, Japan.